From Seekingalpha · · 30s
Cogent: Valuation Leaves No Room for Error
Cogent's promising data faces tight valuation margins.
In brief
Cogent's promising data faces tight valuation margins. Cogent Biosciences' bezuclastinib shows strong results but trading near fair value with little room for error. Originally reported by Seekingalpha.
Cogent's valuation
Cogent Biosciences trades near $29.83 fair value with little room for error.
Bezuclastinib trial results
Bezuclastinib's pivotal GIST trial showed 16.5 months median progression-free survival versus 9.2 months for sunitinib.
FDA decisions and cash balance
Three FDA decisions starting November 30, 2026, and $791.1 million cash balance support commercialization.
The short version
Cogent Biosciences' bezuclastinib shows strong results but trading near fair value with little room for error.
Read the TL;DR — this story on one card.
